T-cell and antibody response characterisation of a new recombinant pre- S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2528-2537

  Jones, Christopher D ^a   Page, Mark ^a   Bacon, Andrew ^a   Cahill, Edward ^b   Bentley, Matthew ^b   Chatfield, Steven N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Gaskill Road Speke L24 9GR   (United Kingdom)

Author keywords

Antibody responses; Hepagene(TM) vaccine; T cell responses

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; DRUG POTENCY; HEPATITIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTEIN PRECURSORS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0033522817     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00061-4     Document Type: Article

References (26)

1. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178-180.
2. Andre F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 8:1990;S74-S78.
3. Alper C.A. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet. 12:1995;171-181.
4. Salazar M., Deulofeut H., Granja C., Deulofeut R., Yunis D.E., Marcus-Bagley D., Awdeh Z., Alper C.A., Yunis E.J. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics. 41:1995;366-374.
5. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibodies following hepatitis B vaccination in Minnesota health care workers. JAMA. 270:1993;2935-2939.
6. Emini E.A., Ellis R.W., Miller W.J., McAleer W.J., Scolnick E.M., Gerety R.J. Production and immunological analysis of recombinant hepatitis B vaccine. J Infect. 13:1986;3-9.
7. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., Ostrow D.G., O'Malley P.M., Penley K.A., Altman N.L., Braff E., Shipman G.F., Coleman P.J., Mandel E.J. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 315:1986;209-214.
8. Coursaget P., Chotard J., Vincelot P., Diop-Mar I., Yvonnet B., Sarr M., N'doye R., Chiron I.P. Seven year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet. ii:1986;1143-1145.
9. Neurath A.R., Kent S.B.H., Strick N., Stark D., Sproul P. Genetic restriction of immune responsiveness to synthetic peptides corresponding to sequences in the pre-S region of the hepatitis B virus (HBV) envelope gene. J Med Virol. 17:1985;119-125.
10. Milich D.R., McLachlan A., Chisari F.V., Kent S.B.H., Thornton G.B. Immune response to the pre-S1 region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T-cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol. 137:1986;315-322.
11. Shouval D., Ilan Y., Adler R., Deepen R., Panet A., Even-Chen Z., Gorecki M., Gerlich W.H. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1, and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 12:1994;1453-1459.
12. Itoh Y., Takai E., Ohnuma H., Kitajima K., Tsuda F., Machida A., Mishiro S., Nakamura T., Miyakawa Y., Mayumi M. A synthetic peptide vaccine involving the product of the pre-S2 region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA. 83:1986;9174-9178.
13. Cupps T.R., Tibbles J., Hurni W.M., Miller W.J., Ellis R.W., Milich D., Wetter N. In vitro T-cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2+S vaccine recipients. J Immunol. 151:1993;3353-3360.
14. Neurath A.R., Kent S.B.H., Strick N., Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 46:1986;429-436.
15. Machida A., Kishimoto S., Ohnuma H., Baba K., Ito Y., Miyamoto H., Funatsu G., Oda K., Usuda S., Togami S., Nakamura T., Miyakawa Y., Mayumi M. A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology. 86:1984;910-918.
16. Zuckerman J.N., Sabin C., Craig F.M., Williams A., Zuckerman A.J. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ. 314:1997;329-333.
17. Stahl S., Mackay P., Magazin M., Bruce S., Murray K. Hepatitis B core antigen: synthesis in Escherichia coli and application in diagnosis. Proc Natl Acad Sci USA. 79:1982;1606-1610.
18. Clarke B.E., Brown A.L., Grace K.G., Al E. Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B core particles produced in bacteria. J Gen Virol. 71:1990;1109-1117.
19. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T-cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 136:1986;2348-2357.
20. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
21. Milich D.R., McLachlan A., Moriarty A., Thornton G.B. A single 10-residue pre-S(1) peptide can prime T-cell help for antibody production to multiple epitopes within the pre-S(1), pre-S(2) and S regions of HBsAg. J Immunol. 138:1987;4457-4465.
22. Milich D.R. Immune response to hepatitis B virus proteins: relevance of the murine model. Semin Liver Dis. 11:1991;93-112.
23. Bomford R., Stapleton M., Winsor S., McKnight A., Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retrovir. 8:1992;1765-1771.
24. Milich D.R., Schodel F., Hughes J.L., Jones J.E., Peterson D.L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol. 71:1997;2192-2201.
25. Gajewski T.F., Pinnas M., Wong T., Fitch F.W. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol. 146:1991;1750-1758.
26. Bertino J.S. Jr., Tirrell P., Greenberg R.N., Keyserling H.L., Poland G.A., Gump D., Kumar M.L., Ramsey K. A comparative trial of standard or high dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1 and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis. 175:1997;678-681.